Sep 12, 2019 7:00am EDT Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference
Sep 4, 2019 7:00am EDT Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
Aug 21, 2019 7:00am EDT Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
Aug 20, 2019 7:00am EDT Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
Aug 12, 2019 8:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Jul 25, 2019 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL